Our products

CNX Therapeutics commercialises the speciality brand CNS drug Latuda in the UK and direct markets across Europe. In addition, we manage a portfolio of niche hospital products for a range of therapy areas including oncology, anti-infectives and endocrinology.

We are seeking to expand our product portfolio and are open to in-licensing, co-promotion, revenue-sharing, and other partnering opportunities.

Please also reach out to us to discuss out-licensing opportunities available for global commercialisation.